citalopram has been researched along with Genetic Predisposition in 27 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "SERT gene polymorphisms in 270 non-depressed first-ever acute ischemic stroke patients randomized to citalopram, n = 130, or placebo, n = 140, were investigated." | 5.30 | Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation. ( Andersen, G; Buttenschøn, HN; Damsbo, AG; Johnsen, SP; Kraglund, KL; Mortensen, JK, 2019) |
| " A total of 796 adult patients with major depressive disorder who were treated with a flexible dosage of escitalopram or nortriptyline in Genome-based Therapeutic Drugs for Depression (GENDEP) were included in the sample and provided data on suicidal ideation." | 2.74 | Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. ( Aitchison, KJ; Bonvicini, C; Craig, I; Farmer, AE; Gray, J; Gupta, B; Hauser, J; Henigsberg, N; Huezo-Diaz, P; Jorgensen, L; Kalember, P; Kapelski, P; Lewis, CM; Maier, W; Marusic, A; McGuffin, P; Mors, O; Perroud, N; Petrovic, A; Placentino, A; Rietschel, M; Schulze, TG; Smith, R; Souery, D; Uher, R; Zobel, A, 2009) |
| "As depression is known to be a risk factor for suicide and many antidepressants are P-gp substrates, it has been speculated that inadequate antidepressant treatment response or adverse side effects could be involved." | 1.48 | Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females. ( Haukka, J; Palo, JU; Rahikainen, AL; Sajantila, A, 2018) |
| "The manifestations of daytime somnolence and abnormal sleep behavior have been described in SCA type 3 (SCA3) and SCA type 6 (SCA6), but as yet have not been described in SCA type 1 (SCA1)." | 1.36 | Excessive daytime somnolence in spinocerebellar ataxia type 1. ( Cunnington, D; Dang, D, 2010) |
| "We sought to determine whether clinical response or tolerance to the Selective Serotonin Reuptake Inhibitor (SSRI) citalopram is associated with genetic polymorphisms in potentially relevant pharmacokinetic enzymes." | 1.35 | Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. ( Hamilton, SP; Jenkins, GD; Kraft, JB; McGrath, PJ; Peters, EJ; Reinalda, MS; Slager, SL, 2008) |
| "Citalopram was administered for 8 weeks to the 83 patients who completed this study." | 1.33 | Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder. ( Choi, MJ; Kang, RH; Lee, MS; Lim, SW; Oh, KS, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 18 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rahikainen, AL | 1 |
| Palo, JU | 1 |
| Haukka, J | 1 |
| Sajantila, A | 1 |
| Zwicker, A | 1 |
| Fabbri, C | 1 |
| Rietschel, M | 2 |
| Hauser, J | 2 |
| Mors, O | 2 |
| Maier, W | 2 |
| Zobel, A | 2 |
| Farmer, A | 1 |
| Aitchison, KJ | 2 |
| McGuffin, P | 2 |
| Lewis, CM | 2 |
| Uher, R | 2 |
| Damsbo, AG | 1 |
| Kraglund, KL | 1 |
| Buttenschøn, HN | 1 |
| Johnsen, SP | 1 |
| Andersen, G | 1 |
| Mortensen, JK | 1 |
| Sanders, BK | 1 |
| Macoveanu, J | 1 |
| Knorr, U | 1 |
| Skimminge, A | 1 |
| Søndergaard, MG | 1 |
| Jørgensen, A | 1 |
| Fauerholdt-Jepsen, M | 1 |
| Paulson, OB | 1 |
| Knudsen, GM | 1 |
| Siebner, HR | 1 |
| Kessing, LV | 1 |
| Wielpuetz, C | 1 |
| Kuepper, Y | 1 |
| Grant, P | 1 |
| Munk, AJ | 1 |
| Hennig, J | 1 |
| Ozbey, G | 1 |
| Yucel, B | 1 |
| Taycan, SE | 1 |
| Kan, D | 1 |
| Bodur, NE | 1 |
| Arslan, T | 1 |
| Percin, F | 1 |
| Yuksel, N | 1 |
| Guzey, C | 1 |
| Uluoglu, C | 1 |
| Chang, HS | 1 |
| Won, E | 1 |
| Lee, HY | 1 |
| Ham, BJ | 1 |
| Lee, MS | 2 |
| Basu, A | 1 |
| Chadda, RK | 1 |
| Sood, M | 1 |
| Kaur, H | 1 |
| Kukreti, R | 1 |
| Eyre, HA | 1 |
| Eskin, A | 1 |
| Nelson, SF | 1 |
| St Cyr, NM | 1 |
| Siddarth, P | 1 |
| Baune, BT | 1 |
| Lavretsky, H | 1 |
| Kang, HJ | 1 |
| Bae, KY | 1 |
| Kim, SW | 1 |
| Shin, IS | 1 |
| Hong, YJ | 1 |
| Ahn, Y | 1 |
| Jeong, MH | 1 |
| Yoon, JS | 1 |
| Kim, JM | 1 |
| Belzeaux, R | 1 |
| Lin, CW | 1 |
| Ding, Y | 1 |
| Bergon, A | 1 |
| Ibrahim, EC | 1 |
| Turecki, G | 1 |
| Tseng, G | 1 |
| Sibille, E | 1 |
| Tsai, SJ | 2 |
| Hong, CJ | 2 |
| Liou, YJ | 2 |
| Yu, YW | 2 |
| Chen, TJ | 2 |
| Hou, SJ | 2 |
| Yen, FC | 2 |
| Perroud, N | 1 |
| Smith, R | 1 |
| Huezo-Diaz, P | 1 |
| Marusic, A | 1 |
| Placentino, A | 1 |
| Henigsberg, N | 1 |
| Souery, D | 1 |
| Kapelski, P | 1 |
| Bonvicini, C | 1 |
| Jorgensen, L | 1 |
| Petrovic, A | 1 |
| Kalember, P | 1 |
| Schulze, TG | 1 |
| Gupta, B | 1 |
| Gray, J | 1 |
| Farmer, AE | 1 |
| Craig, I | 1 |
| Chen, ML | 1 |
| Garriock, HA | 2 |
| Hamilton, SP | 3 |
| Kraft, JB | 2 |
| Shyn, SI | 1 |
| Peters, EJ | 2 |
| Yokoyama, JS | 1 |
| Jenkins, GD | 2 |
| Reinalda, MS | 2 |
| Slager, SL | 2 |
| McGrath, PJ | 2 |
| Dang, D | 1 |
| Cunnington, D | 1 |
| Piubelli, C | 2 |
| Vighini, M | 2 |
| Mathé, AA | 2 |
| Domenici, E | 2 |
| Carboni, L | 2 |
| Clark, SL | 1 |
| Adkins, DE | 1 |
| Aberg, K | 1 |
| Hettema, JM | 1 |
| McClay, JL | 1 |
| Souza, RP | 1 |
| van den Oord, EJ | 1 |
| Buyko, E | 1 |
| Beisswanger, E | 1 |
| Hahn, U | 1 |
| Choi, MJ | 1 |
| Kang, RH | 1 |
| Lim, SW | 1 |
| Oh, KS | 1 |
| Nierenberg, AA | 1 |
| Alpert, JE | 1 |
| Gaynes, BN | 1 |
| Warden, D | 1 |
| Wisniewski, SR | 1 |
| Biggs, MM | 1 |
| Trivedi, MH | 2 |
| Barkin, JL | 1 |
| Rush, AJ | 2 |
| Perlis, RH | 1 |
| Moorjani, P | 1 |
| Fagerness, J | 1 |
| Purcell, S | 1 |
| Fava, M | 1 |
| Smoller, JW | 1 |
| Gurwitz, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Methylphenidate to Improve Clinical Outcomes in Geriatric Depression: A Double-blind Placebo-Controlled Trial of Methylphenidate (Ritalin) Augmentation of Citalopram (Celexa) in Depressed Elderly Patients[NCT00602290] | Phase 4 | 181 participants (Actual) | Interventional | 2008-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hamilton Depression Rating Scale (HDRS) is a 24-item depression scale and the total score is summed with a minimum score=0 and maximum score=76. There are no subscales and the higher values represent a worse outcome. Outcomes are measured and defined as follows: 1) Response will be defined as HDRS scores of 10 or less; 2) Sustained response will be defined as maintained response at week 16; 4) Remission will be defined as HDRS scores of 6 or less. (NCT00602290)
Timeframe: Maintained response measured at Week 16
| Intervention | units on a scale (Mean) |
|---|---|
| 1 - Citalopram + Placebo | 18.3 |
| 2 - Methylphenidate + Placebo | 18.7 |
| 3 - Methylphenidate + Citalopram | 19.8 |
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) is a 16 item self-administered questionnaire that captures life satisfaction over the past week. Each question is rated on a 5 point scale from 1 (Very Poor) to 5 (Very Good). The total score is reported for items 1-14. The minimum raw score on the Q-LES-Q-SF is 14, and the maximum score is 70 with higher values representing a better outcome. (NCT00602290)
Timeframe: Measured at Baseline and Week 16
| Intervention | units on a scale (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| 1 - Citalopram + Placebo | 45.50 | 54.45 |
| 2 - Methylphenidate + Placebo | 47.06 | 53.54 |
| 3 - Methylphenidate + Citalopram | 47.52 | 57.79 |
1 review available for citalopram and Genetic Predisposition
| Article | Year |
|---|---|
Flowers for Algernon: steroid dysgenesis, epigenetics and brain disorders.
Topics: Animals; Brain; Child; Child Development Disorders, Pervasive; Citalopram; Disease Models, Animal; E | 2012 |
10 trials available for citalopram and Genetic Predisposition
| Article | Year |
|---|---|
Genetic disposition to inflammation and response to antidepressants in major depressive disorder.
Topics: Adrenergic Uptake Inhibitors; Adult; C-Reactive Protein; Citalopram; Depressive Disorder, Major; Fem | 2018 |
Serotonergic Regulation and Cognition after Stroke: The Role of Antidepressant Treatment and Genetic Variation.
Topics: Aged; Antidepressive Agents, Second-Generation; Citalopram; Cognition; Cognition Disorders; Denmark; | 2019 |
Altered reward processing in the orbitofrontal cortex and hippocampus in healthy first-degree relatives of patients with depression.
Topics: Adult; Citalopram; Depressive Disorder, Major; Double-Blind Method; Family; Female; Genetic Predispo | 2014 |
Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dopamine Upt | 2016 |
BDNF val66met polymorphism and depressive disorders in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Ci | 2016 |
Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project.
Topics: Adult; Antidepressive Agents; Brain-Derived Neurotrophic Factor; Citalopram; Depressive Disorder, Ma | 2009 |
Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequ | 2009 |
Pharmacogenomic study of side-effects for antidepressant treatment options in STAR*D.
Topics: Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Drug-Related Side Effects | 2012 |
Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.
Topics: Adult; Age of Onset; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Cogniti | 2008 |
Pharmacogenetic analysis of genes implicated in rodent models of antidepressant response: association of TREK1 and treatment resistance in the STAR(*)D study.
Topics: Adolescent; Adult; Aged; Animals; Antidepressive Agents; Brain Chemistry; Citalopram; Depressive Dis | 2008 |
16 other studies available for citalopram and Genetic Predisposition
| Article | Year |
|---|---|
Post-mortem analysis of suicide victims shows ABCB1 haplotype 1236T-2677T-3435T as a candidate predisposing factor behind adverse drug reactions in females.
Topics: Adult; Alleles; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; Autopsy; Cital | 2018 |
Variations in central serotonergic activity - relevance of the 5-HTTLPR, life events and their interaction.
Topics: Adolescent; Adult; Citalopram; Depression; Depressive Disorder; Double-Blind Method; Female; Genetic | 2015 |
ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population.
Topics: Adult; Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B; Cita | 2014 |
Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants.
Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Case-Control Studies; Citalopram; Cortico | 2015 |
Association of serotonin transporter (SLC6A4) and receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study.
Topics: Adult; Citalopram; Depressive Disorder, Major; Female; Gene Frequency; Genetic Association Studies; | 2015 |
Predisposition to treatment response in major depressive episode: A peripheral blood gene coexpression network analysis.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Cohort Studies; Depressive Disorder, Ma | 2016 |
Tryptophan hydroxylase 2 gene is associated with major depression and antidepressant treatment response.
Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Gene Frequ | 2009 |
Genetic studies of drug response and side effects in the STAR*D study, part 2.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Genetic Markers; Genetic Predispositi | 2009 |
A genomewide association study of citalopram response in major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Bone Morphogenetic Protein 7; Citalopram; Cluster Analysis | 2010 |
Excessive daytime somnolence in spinocerebellar ataxia type 1.
Topics: Activities of Daily Living; Amantadine; Ataxin-1; Ataxins; Brain Stem; Cerebellum; Citalopram; Dextr | 2010 |
Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Cytoskeleton; Depre | 2011 |
Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background.
Topics: Animals; Animals, Newborn; Antidepressive Agents, Second-Generation; Citalopram; Depression; Disease | 2011 |
The extraction of pharmacogenetic and pharmacogenomic relations--a case study using PharmGKB.
Topics: Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Citalopram; Computational Biology; Cytochrome P-450 | 2012 |
Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder.
Topics: Adult; Aged; Amino Acid Substitution; Antidepressive Agents, Second-Generation; Anxiety Disorders; B | 2006 |
Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample.
Topics: Case-Control Studies; Citalopram; Clinical Trials as Topic; Cytochrome P-450 Enzyme System; Depressi | 2008 |
Too much hypothalamic serotonin transporter is bad for your mood.
Topics: Adolescent; Alleles; Carrier Proteins; Child; Citalopram; Depression; Genetic Predisposition to Dise | 2001 |